Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geon Kim

Showing results (1-10 of 355) with videos related to

Pageof 36
Sort By:
Archives of Pharmacal Research|September 4, 2009
A special issue edited by Dr. Louis J. Ignarro, A Nobel Prize LaureateSang Geon Kim
Toxicological Research|October 2, 2023
Effects of toxicants on endoplasmic reticulum stress and hepatic cell fate determinationJihoon Tak, Sang Geon Kim
Biological & Pharmaceutical Bulletin|June 1, 2022
Pharmacology of Antagonism of GPCRHitoshi Kurose, Sang Geon Kim
The Journal of Biological Chemistry|August 28, 2003
Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activationIl Je Cho, Sang Geon Kim
Stem Cell Investigation|November 22, 2016
miRNA-324, a potential therapeutic target for paracetamol-induced liver injuryHong Min Wu, Sang Geon Kim
Clinical and Molecular Hepatology|September 21, 2020
Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseasesYun Seok Kim, Sang Geon Kim
PPAR Research|September 4, 2010
AMPK-Dependent Metabolic Regulation by PPAR AgonistsWoo Hyung Lee, Sang Geon Kim
Archives of Pharmacal Research|September 11, 2004
PKC downstream of Pl3-kinase regulates peroxynitrite formation for Nrf2-mediated GSTA2 inductionSang Geon Kim, Sun Ok Kim
Molecular Pharmacology|June 18, 2005
Enhanced CCAAT/enhancer-binding protein beta-liver-enriched inhibitory protein production by Oltipraz, which accompanies CUG repeat-binding protein-1 (CUGBP1) RNA-binding protein activation, leads to inhibition of preadipocyte differentiationEun Ju Bae, Sang Geon Kim
Archives of Pharmacal Research|July 13, 2014
Autophagy and microRNA dysregulation in liver diseasesKyu Min Kim, Sang Geon Kim
Pageof 36

Showing results (1-10 of 355) with videos related to

Sort By:
Pageof 36
Archives of Pharmacal Research|September 4, 2009
A special issue edited by Dr. Louis J. Ignarro, A Nobel Prize LaureateSang Geon Kim
Toxicological Research|October 2, 2023
Effects of toxicants on endoplasmic reticulum stress and hepatic cell fate determinationJihoon Tak, Sang Geon Kim
Biological & Pharmaceutical Bulletin|June 1, 2022
Pharmacology of Antagonism of GPCRHitoshi Kurose, Sang Geon Kim
The Journal of Biological Chemistry|August 28, 2003
Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activationIl Je Cho, Sang Geon Kim
Stem Cell Investigation|November 22, 2016
miRNA-324, a potential therapeutic target for paracetamol-induced liver injuryHong Min Wu, Sang Geon Kim
Clinical and Molecular Hepatology|September 21, 2020
Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseasesYun Seok Kim, Sang Geon Kim
PPAR Research|September 4, 2010
AMPK-Dependent Metabolic Regulation by PPAR AgonistsWoo Hyung Lee, Sang Geon Kim
Archives of Pharmacal Research|September 11, 2004
PKC downstream of Pl3-kinase regulates peroxynitrite formation for Nrf2-mediated GSTA2 inductionSang Geon Kim, Sun Ok Kim
Molecular Pharmacology|June 18, 2005
Enhanced CCAAT/enhancer-binding protein beta-liver-enriched inhibitory protein production by Oltipraz, which accompanies CUG repeat-binding protein-1 (CUGBP1) RNA-binding protein activation, leads to inhibition of preadipocyte differentiationEun Ju Bae, Sang Geon Kim
Archives of Pharmacal Research|July 13, 2014
Autophagy and microRNA dysregulation in liver diseasesKyu Min Kim, Sang Geon Kim
Pageof 36